CPF Inhibitors
Chemical inhibitors of CPF can exert their inhibitory effects through various biochemical and cellular pathways. Trichostatin A, for instance, inhibits histone deacetylase (HDAC), which results in hyperacetylated histones. This alteration in chromatin structure can impede the access of CPF to DNA, thereby inhibiting its function. Similarly, Chlorpromazine blocks dopamine receptors and disrupts downstream dopamine signaling pathways that are crucial for CPF-mediated cellular processes. Imatinib, a tyrosine kinase inhibitor, can impede CPF activity by reducing its phosphorylation state, which is essential for its activation, or by altering signaling cascades CPF is involved in. LY294002 and Wortmannin both act as inhibitors of phosphoinositide 3-kinases (PI3K), and their inhibition of the PI3K/AKT signaling pathway can affect CPF's role in cellular growth and survival. U0126 and PD98059 both target MEK1/2 and inhibit the MAPK/ERK pathway, potentially disrupting CPF's function in cellular proliferation or stress response mechanisms.
In addition to the above, SB203580 inhibits p38 MAP kinase, and by disrupting the p38 MAPK signaling pathways, can affect CPF's role in processes like inflammation or differentiation. Rapamycin targets mTOR and by inhibiting this pathway, can impact CPF's involvement in protein synthesis and cell growth. Y-27632 inhibits ROCK kinase, affecting the actin cytoskeleton and cell motility pathways, which can be crucial if CPF is involved in cellular structure or migration. SP600125 inhibits JNK, which leads to an inhibition of CPF by interfering with pathways involved in apoptosis, neurogenesis, or cellular stress responses. Lastly, Bortezomib inhibits the 26S proteasome, which prevents the degradation of regulatory proteins that control CPF function, thus indirectly inhibiting CPF's activity within the cell cycle and apoptosis processes. Each of these inhibitors targets specific pathways or cellular processes that are known to be involved in the regulation or activity of CPF, thereby leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Inhibits histone deacetylase (HDAC), leading to increased acetylation of histones and affecting gene expression, which can inhibit CPF by altering the chromatin structure and accessibility of the DNA for proteins like CPF that need to bind to DNA to function. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Blocks dopamine receptors, which can inhibit CPF by altering downstream dopamine signaling pathways that CPF may be involved in, specifically those pathways that are crucial for CPF-mediated cellular processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Specifically inhibits certain tyrosine kinases, which are upstream regulators of many signaling pathways, potentially including those that CPF is involved in, thus inhibiting CPF activity by reducing its phosphorylation state or by altering signaling cascades necessary for CPF's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, which can inhibit CPF by blocking the PI3K/AKT signaling pathway, thereby affecting downstream processes that CPF may be part of, particularly those involved in cellular growth and survival where CPF activity is essential. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Specifically inhibits MEK1/2, which can inhibit CPF by blocking the MAPK/ERK pathway, a pathway that CPF might be involved in, especially if CPF's function is associated with cellular proliferation or stress responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAP kinase, which can inhibit CPF by disrupting the p38 MAPK signaling pathways, potentially affecting CPF's role in processes like inflammation or differentiation where p38 MAPK activity is essential. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which can inhibit CPF by affecting the mTOR signaling pathway, particularly impacting CPF's role in protein synthesis and cell growth where mTOR's regulatory function is crucial. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Acts as an inhibitor of PI3K, similar to LY294002, and can inhibit CPF by blocking the PI3K/AKT pathway, potentially affecting CPF's activity in processes such as cell survival and metabolism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which can inhibit CPF by blocking the MAPK/ERK signaling pathway, potentially affecting CPF's role in cellular proliferation, differentiation, or response to external stimuli. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK kinase, which can inhibit CPF by affecting the actin cytoskeleton and cell motility pathways, where CPF may be involved, particularly if CPF has a role in cellular structure or migration. | ||||||